Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Olesen, M N ; Nilsson, A C ; Pihl-Jensen, G ; Soelberg, K K ; Olsen, D A ; Brandslund, I ; Lillevang, S T ; Madsen, J S ; Frederiksen, J L ; Asgari, N. / Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13. In: Multiple Sclerosis and Related Disorders. 2020 ; Vol. 44. pp. 102281.

Bibtex

@article{9bdc2a70e4204653af3dd3098fb93a90,
title = "Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13",
abstract = "BACKGROUND: Elevation of CXCL13, a key regulator of B-cell recruitment in cerebrospinal fluid (CSF) is implicated in multiple sclerosis (MS).OBJECTIVE: to evaluate if measurement of CXCL13 using a highly sensitive assay is of value in acute optic neuritis (ON) patients for the prediction of later MS.METHOD: CXCL13 was measured by Simoa in two independent treatment-na{\"i}ve ON cohorts, a training cohort (TC, n = 33) originating from a population-based cohort, a validation cohort (VC, n = 30) consecutively collected following principles for population studies. Prospectively, 14/33 TC and 12/30 VC patients progressed to MS (MS-ON) while 19/33 TC and 18/30 VC patients, remained as isolated ON (ION).RESULTS: CXCL13 was detectable in all samples and were higher in ON compared with healthy controls (HC) (p = 0.012). In the TC, CSF levels in MS-ON were higher compared with ION patients and HC (p = 0.0001 and p<0.0001). In the VC, we confirmed the increase of CXCL13 in MS-ON compared to ION (p = 0.0091). Logistic regression analysis revealed an area under receiver operating characteristic curve of 0.83 [95% C.I: 0.73-0.93].CONCLUSIONS: The highly sensitive CXCL13 Simoa assay demonstrated ability to identify ON patients and separate MS-ON from ION, and predictive diagnostic values indicates a promising potential of this assay.",
author = "Olesen, {M N} and Nilsson, {A C} and G Pihl-Jensen and Soelberg, {K K} and Olsen, {D A} and I Brandslund and Lillevang, {S T} and Madsen, {J S} and Frederiksen, {J L} and N Asgari",
note = "Copyright {\textcopyright} 2020 Elsevier B.V. All rights reserved.",
year = "2020",
month = sep,
doi = "10.1016/j.msard.2020.102281",
language = "English",
volume = "44",
pages = "102281",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13

AU - Olesen, M N

AU - Nilsson, A C

AU - Pihl-Jensen, G

AU - Soelberg, K K

AU - Olsen, D A

AU - Brandslund, I

AU - Lillevang, S T

AU - Madsen, J S

AU - Frederiksen, J L

AU - Asgari, N

N1 - Copyright © 2020 Elsevier B.V. All rights reserved.

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: Elevation of CXCL13, a key regulator of B-cell recruitment in cerebrospinal fluid (CSF) is implicated in multiple sclerosis (MS).OBJECTIVE: to evaluate if measurement of CXCL13 using a highly sensitive assay is of value in acute optic neuritis (ON) patients for the prediction of later MS.METHOD: CXCL13 was measured by Simoa in two independent treatment-naïve ON cohorts, a training cohort (TC, n = 33) originating from a population-based cohort, a validation cohort (VC, n = 30) consecutively collected following principles for population studies. Prospectively, 14/33 TC and 12/30 VC patients progressed to MS (MS-ON) while 19/33 TC and 18/30 VC patients, remained as isolated ON (ION).RESULTS: CXCL13 was detectable in all samples and were higher in ON compared with healthy controls (HC) (p = 0.012). In the TC, CSF levels in MS-ON were higher compared with ION patients and HC (p = 0.0001 and p<0.0001). In the VC, we confirmed the increase of CXCL13 in MS-ON compared to ION (p = 0.0091). Logistic regression analysis revealed an area under receiver operating characteristic curve of 0.83 [95% C.I: 0.73-0.93].CONCLUSIONS: The highly sensitive CXCL13 Simoa assay demonstrated ability to identify ON patients and separate MS-ON from ION, and predictive diagnostic values indicates a promising potential of this assay.

AB - BACKGROUND: Elevation of CXCL13, a key regulator of B-cell recruitment in cerebrospinal fluid (CSF) is implicated in multiple sclerosis (MS).OBJECTIVE: to evaluate if measurement of CXCL13 using a highly sensitive assay is of value in acute optic neuritis (ON) patients for the prediction of later MS.METHOD: CXCL13 was measured by Simoa in two independent treatment-naïve ON cohorts, a training cohort (TC, n = 33) originating from a population-based cohort, a validation cohort (VC, n = 30) consecutively collected following principles for population studies. Prospectively, 14/33 TC and 12/30 VC patients progressed to MS (MS-ON) while 19/33 TC and 18/30 VC patients, remained as isolated ON (ION).RESULTS: CXCL13 was detectable in all samples and were higher in ON compared with healthy controls (HC) (p = 0.012). In the TC, CSF levels in MS-ON were higher compared with ION patients and HC (p = 0.0001 and p<0.0001). In the VC, we confirmed the increase of CXCL13 in MS-ON compared to ION (p = 0.0091). Logistic regression analysis revealed an area under receiver operating characteristic curve of 0.83 [95% C.I: 0.73-0.93].CONCLUSIONS: The highly sensitive CXCL13 Simoa assay demonstrated ability to identify ON patients and separate MS-ON from ION, and predictive diagnostic values indicates a promising potential of this assay.

U2 - 10.1016/j.msard.2020.102281

DO - 10.1016/j.msard.2020.102281

M3 - Journal article

C2 - 32570180

VL - 44

SP - 102281

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -

ID: 61518005